GUIAS HIPERTENSION ARTERIAL.indb - Scc

Revista Colombiana de Cardiología
Febrero 2007
10. Triggle D. Mechanisms of Action of Calcium – Antagonists. In: Epstein M. Calcium
Antagonists in Clinical Medicine. 3 a Edition. Philadelphia: Hanley and Belfus;
2002.
11. Abernethy DR. Pharmacologic and pharmacokinetic profile of mibefradil, a
T- and L-type calcium channel antagonist. Am J Cardiol 1997; 80: 4C-11C.
12. Weiner DA. Calcium channel blockers. Med Clin North Am 1988; 72: 83-115.
13. Cohn JN, Ziesche S, Smith S, et al. Effect of the calcium antagonist felodipine as
supplementary vasodilator therapy in patients with chronic heart failure treated
with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.
Circulation 1997; 96: 856-863.
14. O’Connor CM, Carson PE, Miller AB, et al. Effect of amlodipine on mode of death
among patients with advanced heart failure in the PRAISE trial. Prospective Randomized
Amlodipine Survival Evaluation. Am J Cardiol 1998; 82: 881-887.
15. Packer M, O’Connor CM, Ghaliet JK, et al. Effect of amlodipine on morbidity
and mortality in severe chronic heart failure. Prospective Randomized Amlodipine
Survival Evaluation Study Group. N Engl J Med 1996; 335: 1107-1114.
16. Thackray S, Witte K, Clark AL, Cleland JGF. Clinical trials update: OPTIME-CHF,
PRAISE-2, ALLHAT. Eur J Heart Fail 2000; 2: 209-212.
17. Opie LH. Calcium channel blockers in hypertension: reappraisal after new trials
and major meta-analyses. Am J Hypertens 2001; 14: 1074-1081.
18. Sica DA, Douglas JG. The African American Study of Kidney Disease and
Hypertension (AASK): new findings. J Clin Hypertens 2001; 3: 244-251.
19. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium
antagonists compared with diuretics and beta-blockers on cardiovascular
morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.
Lancet 2000; 356: 359-365.
20. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive
drugs in elderly patients: cardiovascular mortality and morbidity
the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:
1751-1756.
21. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients
randomised to double-blind treatment with a long-acting calcium-channel
blocker or diuretic in the International Nifedipine GITS study: Intervention as a
Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372.
22. Rosei EA, Dal Palu C, Leonetti G, et al. Clinical results of the Verapamil in
Hypertension and Atherosclerosis Study. J Hypertens 1997; 15: 1337-1344.
23. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter
Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial.
JAMA 1996; 276: 785-791.
24. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared
with enalapril on cardiovascular events in patients with non-insulin-dependent
diabetes and hypertension. N Engl J Med 1998; 338: 645-652.
25. National Intervention Cooperative Study in Elderly Hypertensives Study Group,
Randomized double-blind comparison of a calcium antagonist and a diuretic
in elderly hypertensives. Hypertension 1999; 34: 1129-1133.
26. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus
Amlodipine Cardiovascular Events randomized Trial in patients with hypertension
and NIDDM. Diabetes Care 1998; 21: 597-603.
27. Casiglia E, Spolaore P, Mazz A, et al. Effect of two different therapeutic approaches
on total and cardiovascular mortality in a Cardiovascular Study in the Elderly
(CASTEL). Jpn Heart J 1994; 35: 589-600.
28. Abascal VM, Larson MG, Evans JC, et al. Calcium antagonists and mortality
risk in men and women with hypertension in the Framingham Heart Study. Arch
Intern Med 1998; 158: 1882-1886.
29. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of
placebo and active treatment for older patients with isolated systolic hypertension.
The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;
350: 757-764.
30. Epstein M. Calcium antagonists should continue to be used for first-line treatment
of hypertension. Arch Intern Med 1995; 155: 2150-2156.
31. Epstein M. Calcium antagonists: still appropriate as first line antihypertensive
agents. Am J Hypertens 1996; 9: 110-121.
32. Salvetti A, Ghiadoni L. Guidelines for antihypertensive treatment: an update
after ALLHAT study. J Am Soc Nephrol 2004; 15: S51-S54.
33. Epstein M. The calcium antagonist controversy: the emerging importance of
drug formulation as a determinant of risk. Am J Cardiol 1997; 79: 9-19.
Vol. 13 Suplemento 1
ISSN 0120-5633
231
34. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension
in men. A comparison of six antihypertensive agents with placebo. The Department
of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
N Engl J Med 1993; 328: 914-921.
35. Frishman WH, Brobyn R, Brown RD, et al. Amlodipine versus atenolol in essential
hypertension. Am J Cardiol 1994; 73: 50A-54A.
36. Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris.
N Engl J Med 2000; 342: 101-114.
37. Frishman WH, Michaelson MD. Use of calcium antagonists in patients with ischemic
heart disease and systemic hypertension. Am J Cardiol 1997; 79: 33-38.
38. Pine MB, Citron PD, Bailly DJ, et al. Verapamil versus placebo in relieving stable
angina pectoris. Circulation 1982; 65: 17-22.
39. Schrier RW, Estacio RO. Additional follow-up from the ABCD trial in patients with
type 2 diabetes and hypertension. N Engl J Med 2000; 343: 1969-1973.
40. Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments
in preventing cardiovascular events in elderly diabetic patients: results from the
Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study
Group. J Hypertens 2000; 18: 1671-1675.
41. Sareli P, Radevski IV, Valtchanova ZP, et al. Efficacy of different drug classes used
to initiate antihypertensive treatment in black subjects: results of a randomized
trial in Johannesburg, South Africa. Arch Intern Med 2001; 161: 965-971.
42. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/
calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney
Int 1998; 54: 1283-1289.
43. Smolensky MH, Portaluppi F. Chronopharmacology and chronotherapy of
cardiovascular medications: relevance to prevention and treatment of coronary
heart disease. Am Heart J 1999; 137 (suppl): S14-S24.
44. White WB, Anders RJ, MacIntyre JM, et al. Nocturnal dosing of a novel delivery
system of verapamil for systemic hypertension. Am J Cardiol 1995; 76: 375-380.
45. Neutel JM, Alderman M, Anders RJ, Weber MA. Novel delivery system for verapamil
designed to achieve maximal blood pressure control during the early
morning. Am Heart J 1996; 132: 1202-1206.
46. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA. ACTION (A
Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators.
Effect of long acting nifedipine on mortality and cardiovascular morbidity in
patients with symptomatic stable engina and hypertension: the ACTION trial. J
Hypertens 2005; 23: 641-648.
47. Fagard R. Benefits and safety of long-acting calcium antagonists in coronary
artery disease: the ACTION trial. J Hypertens 2005; 23: 489-491.
48. National Collaborating Centre for Chronic Conditions. Hypertension: management
of hypertension in adults in primary care: partial update. London: Royal
College of Physicians; 2006.
49. Staessen JA, Fagard R, Thijs L, et al. Randomized double-blind comparison of
placebo and active treatment for older patients with isolated systolic hypertension
(Syst-Eur). Lancet 1997; 350: 757-764.
50. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension
in the elderly. Systolic Hypertension in China (Syst-China) Collaborative
Group. Arch Intern Med 2000; 160: 211-220.
51. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA. ACTION (A
Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators.
Effect of long acting nifedipine on mortality and cardiovascular morbidity
in patients with symptomatic stable engina and hypertension: the ACTION trial.
J Hypertens 2005; 23: 641-648.
52. Fagard R. Benefits and safety of long-acting calcium antagonists in coronary
artery disease: the ACTION trial. J Hypertens 2005; 23: 489-491.
53. ASCOT
54. Staessen JA, Wang JG, Thijs L, et al. Cardiovascular protection and blood
pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-1315.
55. Turnbull F, for the Blood Pressure Lowering Treatment Trialists´ Collaboration.
Effects of different blood-pressure lowering regimens on major cardiovascular
events: results of prospectively-designed overviews of randomised trials. Lancet
2003; 362: 1527-1535.
56. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes:
a systematic review. Diabetes Care 2004; 27: 247-255.
57. Mancia G, Gras G, Zanchetti A. New-onset diabetes and antihypertensive drugs.
J Hypertens 2006; 24: 3-10.